1. Drucker D.J. The biology of incretin hormones. Cell Metab. 2006;3:153–165. [PubMed] [Google Scholar]
2. Drucker D.J. Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis. . Mol. Endocrinol. 2003;17:161–171. [PubMed] [Google Scholar]
3. Riddle M.C., Drucker D.J. Emerging therapies mimicking the effects of amylin and glucagon-like peptide 1. Diabetes Care. 2006;29:435–449. [PubMed] [Google Scholar]
4. Dupre J., Ross S.A., Watson D., Brown J.C. Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J. Clin. Endocrinol. Metab. 1973;37:826–828. [PubMed] [Google Scholar]
5. Pederson R.A., Schubert H.E., Brown J.C. Gastric inhibitory polypeptide. Its physiologic release and insulinotropic action in the dog. Diabetes. 1975;24:1050–1056. [PubMed] [Google Scholar]
6. Usdin T.B., Mezey E., Button D.C., Brownstein M.J., Bonner T.I. Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain. Endocrinology. 1993;133:2861–2870. [PubMed] [Google Scholar]
7. Mayo K.E., et al. International Union of Pharmacology. XXXV. The glucagon receptor family. . Pharmacol. Rev. 2003;55:167–194. [PubMed] [Google Scholar]
8. Yip R.G., Boylan M.O., Kieffer T.J., Wolfe M.M. Functional GIP receptors are present on adipocytes. Endocrinology. 1998;139:4004–4007. [PubMed] [Google Scholar]
9. Mentlein R., Gallwitz B., Schmidt W.E. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur. J. Biochem. 1993;214:829–835. [PubMed] [Google Scholar]
10. Kieffer T.J., McIntosh C.H., Pederson R.A. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. . Endocrinology. 1995;136:3585–3596. [PubMed] [Google Scholar]
11. Deacon C.F., Nauck M.A., Meier J., Hucking K., Holst J.J. Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. J. Clin. Endocrinol. Metab. 2000;85:3575–3581. [PubMed] [Google Scholar]
12. Gromada J., et al. Glucagon-like peptide 1 (7-36) amide stimulates exocytosis in human pancreatic beta-cells by both proximal and distal regulatory steps in stimulus-secretion coupling. Diabetes. 1998;47:57–65. [PubMed] [Google Scholar]
13. Trumper A., et al. Glucose-dependent insulinotropic polypeptide is a growth factor for beta (INS-1) cells by pleiotropic signaling. Mol. Endocrinol. 2001;15:1559–1570. [PubMed] [Google Scholar]
14. Trumper A., Trumper K., Horsch D. Mechanisms of mitogenic and anti-apoptotic signaling by glucose-dependent insulinotropic polypeptide in beta(INS-1)-cells. J. Endocrinol. 2002;174:233–246. [PubMed] [Google Scholar]
15. Kim S.J., et al. GIP stimulation of pancreatic beta-cell survival is dependent upon phosphatidylinositol 3-kinase (PI3-K)/protein kinase B (PKB) signaling, inactivation of the forkhead transcription factor Foxo1 and downregulation of bax expression. J. Biol. Chem. 2005;280:22297–22307. [PubMed] [Google Scholar]
16. Tseng C.C., Kieffer T.J., Jarboe L.A., Usdin T.B., Wolfe M.M. Postprandial stimulation of insulin release by glucose-dependent insulinotropic polypeptide (GIP). Effect of a specific glucose-dependent insulinotropic polypeptide receptor antagonist in the rat. J. Clin. Invest. 1996;98:2440–2445. [PMC free article] [PubMed] [Google Scholar]
17. Baggio L., Kieffer T.J., Drucker D.J. Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, regulates fasting glycemia and nonenteral glucose clearance in mice. Endocrinology. 2000;141:3703–3709. [PubMed] [Google Scholar]
18. Miyawaki K., et al. Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice. Proc. Natl. Acad. Sci. U. S. A. 1999;96:14843–14847. [PMC free article] [PubMed] [Google Scholar]
19. Miyawaki K., et al. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat. Med. 2002;8:738–742. [PubMed] [Google Scholar]
20. Gault V.A., et al. Chemical ablation of gastric inhibitory polypeptide receptor action by daily (Pro3)GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-related diabetes. Diabetes. 2005;54:2436–2446. [PubMed] [Google Scholar]
21. Nauck M.A., et al. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J. Clin. Invest. 1993;91:301–307. [PMC free article] [PubMed] [Google Scholar]
22. Elahi D., et al. The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects. Regul. Pept. 1994;51:63–74. [PubMed] [Google Scholar]
23. Fehmann H.-C., Goke R., Goke B. Cell and molecular biology of the incretin hormones glucagon-like peptide 1 and glucose-dependent releasing polypeptide. Endocr. Rev. 1995;16:390–410. [PubMed] [Google Scholar]
24. Lynn F.C., et al. Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats. Diabetes. 2001;50:1004–1011. [PubMed] [Google Scholar]
25. Meier J.J., et al. Stimulation of insulin secretion by intravenous bolus injection and continuous infusion of gastric inhibitory polypeptide in patients with type 2 diabetes and healthy control subjects. Diabetes. 2004;53(Suppl. 3):S220–S224. [PubMed] [Google Scholar]
26. Reimer R.A., McBurney M.I. Dietary fiber modulates intestinal proglucagon messenger ribonucleic acid and postprandial secretion of glucagon-like peptide-1 and insulin in rats. Endocrinology. 1996;137:3948–3956. [PubMed] [Google Scholar]
27. Tappenden K.A., Thomson A.B., Wild G.E., McBurney M.I. Short-chain fatty acids increase proglucagon and ornithine decarboxylase messenger RNAs after intestinal resection in rats. JPEN J. Parenter. Enteral Nutr. 1996;20:357–362. [PubMed] [Google Scholar]
28. Tappenden K.A., McBurney M.I. Systemic short-chain fatty acids rapidly alter gastrointestinal structure, function, and expression of early response genes. Dig. Dis. Sci. 1998;43:1526–1536. [PubMed] [Google Scholar]
29. Ulshen M.H., et al. Increased ileal proglucagon expression after jejunectomy is not suppressed by inhibition of bowel growth. Dig. Dis. Sci. 1996;41:677–683. [PubMed] [Google Scholar]
30. Taylor R.G., Beveridge D.J., Fuller P.J. Expression of ileal glucagon and peptide tyrosine-tyrosine genes. Response to inhibition of polyamine synthesis in the presence of massive small-bowel resection. Biochem. J. 1992;286:737–741. [PMC free article] [PubMed] [Google Scholar]
31. Brubaker P.L., Anini Y. Direct and indirect mechanisms regulating secretion of glucagon-like peptide-1 and glucagon-like peptide-2. Can. J. Physiol. Pharmacol. 2003;81:1005–1012. [PubMed] [Google Scholar]
32. Mojsov S., Kopczynski M.G., Habener J.F. Both amidated and nonamidated forms of glucagon-like peptide I are synthesized in the rat intestine and the pancreas. J. Biol. Chem. 1990;265:8001–8008. [PubMed] [Google Scholar]
33. Orskov C., Wettergren A., Holst J.J. Biological effects and metabolic rates of glucagonlike peptide-1 7-36 amide and glucagonlike peptide-1 7-37 in healthy subjects are indistinguishable. . Diabetes. 1993;42:658–661. [PubMed] [Google Scholar]
34. Wettergren A., Pridal L., Wojdemann M., Holst J.J. Amidated and non-amidated glucagon-like peptide-1 (GLP-1): non-pancreatic effects (cephalic phase acid secretion) and stability in plasma in humans. Regul. Pept. 1998;77:83–87. [PubMed] [Google Scholar]
35. Orskov C., Rabenhoj L., Wettergren A., Kofod H., Holst J.J. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes. 1994;43:535–539. [PubMed] [Google Scholar]
36. Vilsboll T., Krarup T., Deacon C.F., Madsbad S., Holst J.J. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes. 2001;50:609–613. [PubMed] [Google Scholar]
37. Hansen L., Deacon C.F., Orskov C., Holst J.J. Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology. 1999;140:5356–5363. [PubMed] [Google Scholar]
38. Deacon C.F., et al. Both subcutaneously and intravenously administered glucagon-like peptide 1 are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes. 1995;44:1126–1131. [PubMed] [Google Scholar]
39. Kreymann B., Williams G., Ghatei M.A., Bloom S.R. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet. 1987;2:1300–1304. [PubMed] [Google Scholar]
40. Mojsov S., Weir G.C., Habener J.F. Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J. Clin. Invest. 1987;79:616–619. [PMC free article] [PubMed] [Google Scholar]
41. Orskov C., Holst J.J., Nielsen O.V. Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. . Endocrinology. 1988;123:2009–2013. [PubMed] [Google Scholar]
42. D’alessio D.A., et al. Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons. J. Clin. Invest. 1996;97:133–138. [PMC free article] [PubMed] [Google Scholar]
43. Edwards C.M., et al. Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39. Diabetes. 1999;48:86–93. [PubMed] [Google Scholar]
44. Wang Z., et al. Glucagon-like peptide 1 is a physiological incretin in rat. J. Clin. Invest. 1995;95:417–421. [PMC free article] [PubMed] [Google Scholar]
45. Schirra J., et al. Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans. J. Clin. Invest. 1998;101:1421–1430. [PMC free article] [PubMed] [Google Scholar]
46. Scrocchi L.A., et al. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide receptor gene. Nat. Med. 1996;2:1254–1258. [PubMed] [Google Scholar]
47. Flamez D., et al. Mouse pancreatic beta cells exhibit preserved glucose competence after disruption of the glucagon-like peptide 1 receptor gene. Diabetes. 1998;47:646–652. [PubMed] [Google Scholar]
48. Wang Y.H., et al. Glucagon-like peptide-1 affects gene transcription and messenger ribonucleic acid stability of components of the insulin secretory system in RIN 1046-38 cells. Endocrinology. 1995;136:4910–4917. [PubMed] [Google Scholar]
49. Wang Y., et al. Glucagon-like peptide-1 can reverse the age-related decline in glucose tolerance in rats. J. Clin. Invest. 1997;99:2883–2889. [PMC free article] [PubMed] [Google Scholar]
50. Zander M., Madsbad S., Madsen J.L., Holst J.J. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet. 2002;359:824–830. [PubMed] [Google Scholar]
51. Degn K.B., et al. One week’s treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes. 2004;53:1187–1194. [PubMed] [Google Scholar]
52. Fehse F., et al. Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. . J. Clin. Endocrinol. Metab. 2005;90:5991–5997. [PubMed] [Google Scholar]
53. Xu G., Stoffers D.A., Habener J.F., Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes. 1999;48:2270–2276. [PubMed] [Google Scholar]
54. Edvell A., Lindstrom P. Initiation of increased pancreatic islet growth in young normoglycemic mice (Umea +/?). Endocrinology. 1999;140:778–783. [PubMed] [Google Scholar]
55. Stoffers D.A., et al. Insulinotropic glucagon-like peptide-1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. Diabetes. 2000;49:741–748. [PubMed] [Google Scholar]
56. Perfetti R., Zhou J., Doyle M.E., Egan J.M. Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology. 2000;141:4600–4605. [PubMed] [Google Scholar]
57. Kim J.G., et al. Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo. Diabetes. 2003;52:751–759. [PubMed] [Google Scholar]
58. Ling Z., et al. Glucagon-like peptide 1 receptor signaling influences topography of islet cells in mice. Virchows Arch. 2001;438:382–387. [PubMed] [Google Scholar]
59. De Leon D.D., et al. Role of endogenous glucagon-like peptide-1 in islet regeneration following partial pancreatectomy. Diabetes. 2003;5252:365–371. [PubMed] [Google Scholar]
60. Li Y., et al. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J. Biol. Chem. 2003;278:471–478. [PubMed] [Google Scholar]
61. Buteau J., et al. Protein kinase Czeta activation mediates glucagon-like peptide-1-induced pancreatic beta-cell proliferation. Diabetes. 2001;50:2237–2243. [PubMed] [Google Scholar]
62. Brubaker P.L., Drucker D.J. Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut and central nervous system. Endocrinology. 2004;145:2653–2659. [PubMed] [Google Scholar]
63. Park S., et al. Exendin-4 uses Irs2 signaling to mediate pancreatic beta cell growth and function. . J. Biol. Chem. 2005;281:1159–1168. [PubMed] [Google Scholar]
64. Buteau J., Spatz M.L., Accili D. Transcription factor FoxO1 mediates glucagon-like peptide-1 effects on pancreatic beta-cell mass. . Diabetes. 2006;55:1190–1196. [PubMed] [Google Scholar]
65. Farilla L., et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology. 2003;144:5149–5158. [PubMed] [Google Scholar]
66. Buteau J., et al. Glucagon-like peptide-1 prevents beta cell glucolipotoxicity. Diabetologia. 2004;47:806–815. [PubMed] [Google Scholar]
67. Collie N.L., Zhu Z., Jordan S., Reeve J.R. Oxyntomodulin stimulates intestinal glucose uptake in rats. Gastroenterology. 1997;112:1961–1970. [PubMed] [Google Scholar]
68. Jarrousse C., Bataille D., Jeanrenaud B. A pure enteroglucagon, oxyntomodulin (glucagon 37), stimulates insulin release in perfused rat pancreas. . Endocrinology. 1984;115:102–105. [PubMed] [Google Scholar]
69. Wynne K., et al. Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial. Int. J. Obes. (Lond.) 2007 In press. [PubMed] [Google Scholar]
70. Wynne K., et al. Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial. . Diabetes. 2005;54:2390–2395. [PubMed] [Google Scholar]
71. Dakin C.L., et al. Oxyntomodulin inhibits food intake in the rat. Endocrinology. 2001;142:4244–4250. [PubMed] [Google Scholar]
72. Baggio L.L., Huang Q., Brown T.J., Drucker D.J. Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. Gastroenterology. 2004;127:546–558. [PubMed] [Google Scholar]
73. Cheeseman C.I., Tsang R. The effect of gastric inhibitory polypeptide and glucagon like peptides on intestinal hexose transport. Am. J. Physiol. Gastrointest. Liver Physiol. 1996;271:G477–G482. [PubMed] [Google Scholar]
74. Boushey R.P., Yusta B., Drucker D.J. Glucagon-like peptide 2 decreases mortality and reduces the severity of indomethacin-induced murine enteritis. Am. J. Physiol. 1999;277:E937–E947. [PubMed] [Google Scholar]
75. Boushey R.P., Yusta B., Drucker D.J. Glucagon-like peptide (GLP)-2 reduces chemotherapy-associated mortality and enhances cell survival in cells expressing a transfected GLP-2 receptor. Cancer Res. 2001;61:687–693. [PubMed] [Google Scholar]
76. Jeppesen P.B., et al. Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon. Gastroenterology. 2001;120:806–815. [PubMed] [Google Scholar]
77. Jeppesen P.B. Clinical significance of GLP-2 in short-bowel syndrome. J. Nutr. 2003;133:3721–3724. [PubMed] [Google Scholar]
78. Jeppesen P.B., et al. Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients. Gut. 2005;54:1224–1231. [PMC free article] [PubMed] [Google Scholar]
79. Meier J.J., et al. Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans. Gastroenterology. 2006;130:44–54. [PubMed] [Google Scholar]
80. Gutniak M., Orskov C., Holst J.J., Ahren B., Efendic S. Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. N. Engl. J. Med. 1992;326:1316–1322. [PubMed] [Google Scholar]
81. Rachman J., et al. Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1(7-36)amide in patients with NIDDM. Diabetes. 1996;45:1524–1530. [PubMed] [Google Scholar]
82. Rachman J., Barrow B.A., Levy J.C., Turner R.C. Near normalization of diurnal glucose concentrations by continuous administration of glucagon-like peptide 1 (GLP-1) in subjects with NIDDM. Diabetologia. 1997;40:205–211. [PubMed] [Google Scholar]
83. Todd J.F., Wilding J.P., Edwards C.M., Ghatei M.A., Bloom S.R. Glucagon-like peptide-1 (GLP-1): a trial of treatment in non-insulin-dependent diabetes mellitus. Eur. J. Clin. Invest. 1997;27:533–536. [PubMed] [Google Scholar]
84. Eng J., Kleinman W.A., Singh L., Singh G., Raufman J.P. Isolation and characterization of exendin 4, an exendin 3 analogue from Heloderma suspectum venom. J. Biol. Chem. 1992;267:7402–7405. [PubMed] [Google Scholar]
85. Goke R., et al. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting β-cells. J. Biol. Chem. 1993;268:19650–19655. [PubMed] [Google Scholar]
86. Chen Y.E., Drucker D.J. Tissue-specific expression of unique mRNAs that encode proglucagon-derived peptides or exendin 4 in the lizard. . J. Biol. Chem. 1997;272:4108–4115. [PubMed] [Google Scholar]
87. Buse J.B., et al. Effects of exenatide (Exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004;27:2628–2635. [PubMed] [Google Scholar]
88. DeFronzo R.A., et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005;28:1092–1100. [PubMed] [Google Scholar]
89. Kendall D.M., et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005;28:1083–1091. [PubMed] [Google Scholar]
90. Heine R.J., et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann. Intern. Med. 2005;143:559–569. [PubMed] [Google Scholar]
91. Harder H., Nielsen L., Tu D.T., Astrup A. The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes. Diabetes Care. 2004;27:1915–1921. [PubMed] [Google Scholar]
92. Madsbad S., Schmitz O., Ranstam J., Jakobsen G., Matthews D.R. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. Diabetes Care. 2004;27:1335–1342. [PubMed] [Google Scholar]
93. Gedulin B.R., et al. Dose-response for glycaemic and metabolic changes 28 days after single injection of long-acting release exenatide in diabetic fatty Zucker rats. Diabetologia. 2005;48:1380–1385. [PubMed] [Google Scholar]
94. Mitani H., Takimoto M., Hughes T.E., Kimura M. Dipeptidyl peptidase IV inhibition improves impaired glucose tolerance in high-fat diet-fed rats: study using a Fischer 344 rat substrain deficient in its enzyme activity. Jpn. J. Pharmacol. 2002;88:442–450. [PubMed] [Google Scholar]
95. Marguet D., et al. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc. Natl. Acad. Sci. U. S. A. 2000;97:6874–6879. [PMC free article] [PubMed] [Google Scholar]
96. Ahren B., Holst J.J., Martensson H., Balkan B. Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice. Eur. J. Pharmacol. 2000;404:239–245. [PubMed] [Google Scholar]
97. Pederson R.A., et al. Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide. Diabetes. 1998;47:1253–1258. [PubMed] [Google Scholar]
98. Ahren B., et al. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. . J. Clin. Endocrinol. Metab. 2004;89:2078–2084. [PubMed] [Google Scholar]
99. Ahren B., et al. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care. 2002;25:869–875. [PubMed] [Google Scholar]
100. Ahren B., Holst J.J., Efendic S. Antidiabetogenic action of cholecystokinin-8 in type 2 diabetes. J. Clin. Endocrinol. Metab. 2000;85:1043–1048. [PubMed] [Google Scholar]
101. Boushey R.P., et al. Hypoglycemia, defective islet glucagon secretion, but normal islet mass in mice with a disruption of the gastrin gene. Gastroenterology. 2003;125:1164–1174. [PubMed] [Google Scholar]
102. Kuntz E., Pinget M., Damge P. Cholecystokinin octapeptide: a potential growth factor for pancreatic beta cells in diabetic rats. Jop. 2004;5:464–475. [PubMed] [Google Scholar]
103. Rooman I., Lardon J., Bouwens L. Gastrin stimulates beta-cell neogenesis and increases islet mass from transdifferentiated but not from normal exocrine pancreas tissue. Diabetes. 2002;51:686–690. [PubMed] [Google Scholar]
104. Rooman I., Bouwens L. Combined gastrin and epidermal growth factor treatment induces islet regeneration and restores normoglycaemia in C57Bl6/J mice treated with alloxan. Diabetologia. 2004;47:259–265. [PubMed] [Google Scholar]
105. Suarez-Pinzon W.L., Yan Y., Power R., Brand S.J., Rabinovitch A. Combination therapy with epidermal growth factor and gastrin increases beta-cell mass and reverses hyperglycemia in diabetic NOD mice. Diabetes. 2005;54:2596–2601. [PubMed] [Google Scholar]
106. Suarez-Pinzon W.L., Lakey J.R., Brand S.J., Rabinovitch A. Combination therapy with epidermal growth factor and gastrin induces neogenesis of human islet beta-cells from pancreatic duct cells and an increase in functional beta-cell mass. J. Clin. Endocrinol. Metab. 2005;90:3401–3409. [PubMed] [Google Scholar]
107. Druce M.R., et al. Ghrelin increases food intake in obese as well as lean subjects. Int. J. Obes. (Lond.) 2005;29:1130–1136. [PubMed] [Google Scholar]
108. Prado C.L., Pugh-Bernard A.E., Elghazi L., Sosa-Pineda B., Sussel L. Ghrelin cells replace insulin-producing beta cells in two mouse models of pancreas development. Proc. Natl. Acad. Sci. U. S. A. 2004;101:2924–2929. [PMC free article] [PubMed] [Google Scholar]
109. Dezaki K., et al. Endogenous ghrelin in pancreatic islets restricts insulin release by attenuating Ca2+ signaling in beta-cells: implication in the glycemic control in rodents. Diabetes. 2004;53:3142–3151. [PubMed] [Google Scholar]
110. Sun Y., Asnicar M., Saha P.K., Chan L., Smith R.G. Ablation of ghrelin improves the diabetic but not obese phenotype of ob/ob mice. Cell Metab. 2006;3:379–386. [PubMed] [Google Scholar]
111. Theander-Carrillo C., et al. Ghrelin action in the brain controls adipocyte metabolism. J. Clin. Invest. 2006;116:1983–1993. doi:10.1172/JCI25811. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
112. Irako T., et al. Ghrelin prevents development of diabetes at adult age in streptozotocin-treated newborn rats. Diabetologia. 2006;49:1264–1273. [PubMed] [Google Scholar]
113. Besterman H.S., et al. Gut hormone release after intestinal resection. Gut. 1982;23:854–861. [PMC free article] [PubMed] [Google Scholar]
114. Besterman H.S., et al. Gut hormones in inflammatory bowel disease. Scand. J. Gastroenterol. 1983;18:845–852. [PubMed] [Google Scholar]
115. Xiao Q., Boushey R.P., Cino M., Drucker D.J., Brubaker P.L. Circulating levels of glucagon-like peptide-2 in human subjects with inflammatory bowel disease. Am. J. Physiol. 2000;278:R1057–R1063. [PubMed] [Google Scholar]
116. Naslund E., Backman L., Holst J.J., Theodorsson E., Hellstrom P.M. Importance of small bowel peptides for the improved glucose metabolism 20 years after jejunoileal bypass for obesity. Obes. Surg. 1998;8:253–260. [PubMed] [Google Scholar]
117. Le Roux C.W., et al. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann. Surg. 2006;243:108–114. [PMC free article] [PubMed] [Google Scholar]
118. Morinigo R., et al. Glucagon-like peptide-1, peptide YY, hunger, and satiety after gastric bypass surgery in morbidly obese subjects. J. Clin. Endocrinol. Metab. 2006;91:1735–1740. [PubMed] [Google Scholar]
119. Patti M.E., et al. Severe hypoglycemia post-gastric bypass requiring partial pancreatectomy: evidence for inappropriate insulin secretion and pancreatic islet hyperplasia. Diabetologia. 2005;4:2236–2240. [PubMed] [Google Scholar]
120. Service G.J., et al. Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery. N. Engl. J. Med. 2005;353:249–254. [PubMed] [Google Scholar]
121. Meier J.J., Butler A.E., Galasso R., Butler P.C. Hyperinsulinemic hypoglycemia after gastric bypass surgery is not accompanied by islet hyperplasia or increased beta-cell turnover. Diabetes Care. 2006;29:1554–1559. [PubMed] [Google Scholar]
122. Jackson R.S., et al. Small-intestinal dysfunction accompanies the complex endocrinopathy of human proprotein convertase 1 deficiency. J. Clin. Invest. 2003;112:1550–1560. doi:10.1172/JCI200318784. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
123. Wang J., et al. Mutant neurogenin-3 in congenital malabsorptive diarrhea. N. Engl. J. Med. 2006;355:270–280. [PubMed] [Google Scholar]
124. Grant S.F., et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat. Genet. 2006;38:320–323. [PubMed] [Google Scholar]
125. Florez J.C., et al. TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N. Engl. J. Med. 2006;355:241–250. [PMC free article] [PubMed] [Google Scholar]
